Infinity Pharmaceuticals Inc. Reports Phase 1 Data Of IPI-145 At Sixth Annual T-Cell Lymphoma Forum

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) reported encouraging data from its ongoing Phase 1 study of IPI-145, its oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with relapsed/refractory T-cell lymphoma, a difficult-to-treat hematologic malignancy (blood cancer) with few available treatment options. Preliminary data showed that IPI-145 is clinically active in patients with T-cell lymphoma, with an overall response rate of 38 percent, including one complete response and nine partial responses among 26 patients evaluable for response. These findings were reported during the 6th Annual T-Cell Lymphoma Forum being held from January 23 – 25, 2014, in San Francisco, CA.

Help employers find you! Check out all the jobs and post your resume.